Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Journavx Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Journavx Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs quantity-limit authorization for Journavx (suzetrigine 50 mg tablets) under the Boeing commercial formulary. It applies when the requested quantity is within or exceeds the program limit.

    Policy Summary
    PayerPrime Therapeutics
    PolicyJournavx Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionFor quantities above 30 tablets per 90 days, submit support for moderate to severe acute pain and one qualifying dose-support pathway.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 tabletsProgram quantity limit
    90 daysQuantity-limit duration
    3 monthsMaximum approval length
    50 mgJournavx tablet strength

    Quantity-Limit Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Quantity-limit approval

    Quantity-limit approval will be granted when ONE of the following is met.

    • Within program limit: The requested quantity (dose) does not exceed the program quantity limit.Does not exceed program quantity limit
    • Above program limit

      • Acute pain use: The requested agent is being used for the treatment of moderate to severe acute pain.Moderate to severe acute pain
      • Qualifying dose-support pathway

        • No maximum FDA-labeled dose: The requested agent does not have a maximum FDA-labeled dose for the requested indication and there is support for therapy with a higher dose for the requested indication.No maximum FDA-labeled dose; support for higher dose
        • Within maximum FDA-labeled dose with alternative-strength rationale: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication and there is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.Does not exceed maximum FDA-labeled dose
        • Above maximum FDA-labeled dose with support: The requested quantity exceeds the maximum FDA-labeled dose for the requested indication and there is support for therapy with a higher dose for the requested indication.Exceeds maximum FDA-labeled dose; support for higher dose

    Initial Quantity-Limit Approval

    Initial quantity-limit approval

    Quantity-limit approval will be granted when ONE of the following is met.

    Quantity-limit approval

    • Within program limit: The requested quantity (dose) does not exceed the program quantity limit.Does not exceed program quantity limit
    • Above program limit

      • Acute pain use: The requested agent is being used for the treatment of moderate to severe acute pain.Moderate to severe acute pain
      • Qualifying dose-support pathway

        • No maximum FDA-labeled dose: The requested agent does not have a maximum FDA-labeled dose for the requested indication and there is support for therapy with a higher dose for the requested indication.No maximum FDA-labeled dose; support for higher dose
        • Within maximum FDA-labeled dose with alternative-strength rationale: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication and there is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.Does not exceed maximum FDA-labeled dose
        • Above maximum FDA-labeled dose with support: The requested quantity exceeds the maximum FDA-labeled dose for the requested indication and there is support for therapy with a higher dose for the requested indication.Exceeds maximum FDA-labeled dose; support for higher dose

    Authorization and Documentation Requirements

    Prior Authorization

    Quantity-Limit Authorization Criteria

    Authorization is approved for up to the program limit of 30 tablets per 90 days. A request exceeding this limit may be approved only when the agent is being used for moderate to severe acute pain and the applicable higher-dose or alternative-strength documentation requirements are met.

    • Requested quantity does not exceed 30 tablets per 90 days; or
    • Requested quantity exceeds the limit, the indication is moderate to severe acute pain, and the higher-dose or alternative-strength criteria below are satisfied.
    • Length of approval: 3 months.
    Documentation Required

    Support for Higher-Dose or Alternative-Strength Requests

    For quantities above the program limit, document why the requested dose or quantity is medically necessary and cannot be managed within the limit. Provide support for higher-dose therapy or, when applicable, explain why the requested quantity cannot be achieved with a lower quantity of a higher-strength tablet.

    • If there is no maximum FDA-labeled dose for the indication, provide support for therapy with a higher dose.
    • If the requested quantity does not exceed the maximum FDA-labeled dose, provide support explaining why the quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose, provide support for therapy with a higher dose.
    • The request must be for treatment of moderate to severe acute pain.
    Denial Risk

    Exceeding the Quantity Limit Without Qualifying Support

    Requests exceeding the 30-tablet-per-90-day limit are at risk for denial when the required clinical indication and supporting documentation are not provided.

    • A quantity above the limit without documentation of moderate to severe acute pain does not meet the criteria.
    • A higher-dose request without support for therapy above the labeled dose, when required, may be denied.
    • An alternative-strength request without an explanation of why a lower quantity of a higher strength cannot be used may be denied.
    • Requests that exceed the limit and do not satisfy one of the qualifying pathways are not approved.

    Policy Background

    Journavx (suzetrigine) 50 mg tablets are subject to a quantity-limit program for the treatment of moderate to severe acute pain. The standard program limit is 30 tablets per 90 days. Requests within the limit may follow the standard pathway; requests above the limit require documentation supporting the applicable FDA-labeled-dose and clinical-need criteria.

    Journavx Quantity Limits

    Quantity Limits
    MedicationJournavx (suzetrigine)
    Strength and dosage form50 mg tablets
    Quantity limit30 tablets per 90 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyJournavx Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionFor quantities above 30 tablets per 90 days, submit support for moderate to severe acute pain and one qualifying dose-support pathway.
    SourceLink
    On This Page
    Quantity-Limit Coverage CriteriaInitial Quantity-Limit ApprovalAuthorization and Documentation RequirementsPolicy BackgroundJournavx Quantity Limits